65,437 trials
Measles/Rubella
Primary: Number of Participants With Serious Adverse Drug Reactions — 7 participants
Nicotine Dependence · Alcohol Dependence
Primary: 4-week Continuous Abstinence From Smoking — 7.9; 10.6 percentage of participants abstinent
Common Cold
Primary: Onset of Warming Sensation — 0.233 Minutes
Lung Cancer
Primary: Progression-free Survival — 3.4; 4.1 months
Mantle Cell Lymphoma
Primary: Maximum Tolerated Dose of Lenalidomide Combined With Bortezomib and Rituximab in Phase I Participants — 10 mg lenalidomide, orally, daily, day 1-14
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1C) at Week 12 — 8.01; 8.00; 7.80; 8.15 percentage of hemoglobin — p=0.5206
Clinical Efficacy
Primary: Horizontal Ridge Dimension — -1.6; -0.3 mm
Immunologic Tests
Primary: Number of Subject Responders With Antigen Specific Lymphocytes T Helper 2 (Th2) Cluster of Differentiation 4+ (CD4+) T Cells Expressing Cytokines — 7; 1; 7; 0 Subjects
Subjects Presenting With Normal Eyes
Primary: TopQ Cut Off — 2.94; 1.5; 2.14; 17.54 microns
Cardiac Arrest
Primary: Number of Participants Who Survive From the Time of Cardiac Arrest to Hospital Discharge — 237; 233; 222 participants
Asthma
Primary: Modified Medication Possession Ratio — .40; .38 fraction of days with medication — p=.002
Bipolar Depression
Primary: Change in Scores on the Montgomery-Asberg Depression Rating Scale (MADRS) — -14.6 units on a scale
Actinic Keratosis
Primary: Actinic Keratoses Reduction Percent — 71.4; 80.2; 72.5; 68.3 percentage
Cardiovascular Disease · Insulin Resistance · Glucose Intolerance
Primary: Change in Insulin Resistance From Baseline to 3 Months, as Measured by HOMA-IR — 3.57; 3.84; 3.81; 5.06 mg*microunits/dL*mL — p=0.34
Lupus Erythematosus, Systemic
Primary: Change From Baseline Serum Interleukin 6 (IL-6) Levels at the End of Active Dosing, Comparing Treatment to Placebo Cohort. — 1.6; 987.7; -82.5; -29.7 percentage change…